GlassScriptPhysician profile
Leslie E Mezei
NPI 1992800429
$689.26
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $53.39 · 2021: $176.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $112.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $111.54 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $98.79 | 2019-2021 | |
| Amgen INC. | $61.19 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $55.08 | 2019 | |
| Pfizer INC. | $53.38 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $45.78 | 2021 | |
| Vifor Pharma, INC. | $34.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.95 | 2019 | |
| Boston Scientific Corporation | $29.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.21 | 2019 | |
| Amarin Pharma, INC. | $14.48 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Mezei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.